Minimal Residual Disease Epidemiology Market - Strategic Insights and Forecasts (2026-2031)

The Minimal Residual Disease Epidemiology market is projected to grow at a CAGR of 6.2% during the forecast period, increasing from USD 2.97 billion in 2026 to USD 4.02 billion by 2031.

The market is driven by rising relapse rates in hematologic malignancies, increasing adoption of high-sensitivity molecular diagnostics, regulatory recognition of MRD endpoints, and expanding use of precision oncology treatment strategies.

Key restraints include variability in MRD detection thresholds, lack of globally standardized clinical guidelines, high costs of sequencing-based diagnostics, and limited access to advanced oncology infrastructure in developing regions.

North America leads the market due to advanced diagnostic infrastructure, strong regulatory support, high oncology spending, and increasing integration of MRD testing into clinical oncology workflows.

The market outlook remains strong as MRD evolves from a research biomarker into a standard clinical oncology tool. Continuous advances in sequencing technologies, liquid biopsy platforms, and precision oncology are expected to further strengthen MRD integration into global cancer management.